- Home
- » Tags
- » Ticlopidine
Top View
- Data Sheet Template
- Ticlopidine-Induced Subacute Cutaneous Lupus Erythematosus: a Case Report and Literature Review
- Advances in Interventional Cardiology New Directions In
- Package Leaflet: Information for the Patient /…/ Ticlopidine Hydrochloride Read All of This Leaflet Carefully Before You Start
- Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current
- Choledyl-Expect-PM-E
- Gangrene of the Fingertips After Bleomycin and Methotrexate
- Pharmacogenomic Associations Tables
- Wo 2010/054158 A2
- HIGHLIGHTS of PRESCRIBING INFORMATION These Highlights Do Not Include All the Information Needed to Use SYMPAZAN® Safely and Ef
- Appendix B - Product Name Sorted by Applicant
- Initial Proposed Smpc Plus Proposed Revisions
- Dye-Staining Angioscopy for Coronary Artery Disease
- Neutrophil Stunning by Metoprolol Reduces Infarct Size
- Fluffy Luminal Surface of the Non-Stenotic Culprit Coronary
- Should You Switch the DAPT Agent a Month After ACS? a Randomized Controlled Trial Says “Yes,” but Current Guidelines Say “No.”
- 2018.01 Platelet-Aggregation Inhibitors.Pdf
- Effect of Chewing Vs Swallowing Ticagrelor On
- Efient, INN-Prasugrel
- The Clinical Effects of Cilostazol on Atherosclerotic Vascular Disease
- Randomized Comparison of Cilostazol Vs Ticlopidine for Antiplatelet Therapy After Coronary Stenting
- Tenncare Attestation List September 1, 2021
- Cangrelor for the Management and Prevention of Arterial Thrombosis
- NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Cohort
- Australian Adverse Drug Reactions Bulletin, May 1998
- Vedani Nicola
- Taking Aim at Wall Teichoic Acid Synthesis: New Biology and New Leads for Antibiotics
- Strong and Selective Inhibitory Effects of the Biflavonoid Selamariscina A
- Intravenous Platelet Blockade with Cangrelor During PCI
- Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans Nagy A
- Preventive Drugs by Condition
- Aspirin and Ticlopidine for Prevention of Recurrent Stroke in Black Patients a Randomized Trial
- 204958Orig1s000
- Should You Switch the DAPT Agent One Month After ACS?
- Australian Adverse Drug Reactions Bulletin, Volume 18, Number
- Environmentally Classified Pharmaceuticals
- 01 Stockley's Herbal Medicines Interactions PRELIMS 1
- Ticagrelor (Brilinta) for Secondary Prevention of Thrombotic Events
- Highlights of Prescribing Information
- Personalizing Oral Antiplatelet Therapy in PCI
- Select Drug List
- Ticagrelor (Brilinta)
- Effects of Different Antihypertensive Drugs on Plasma Fibrinogen in Hypertensive Patients
- In Vitro Characterization of the Human Liver Microsomal Kinetics and Reaction Phenotyping of Olanzapine Metabolism
- A Prospective Randomized Multi-Center Study of Antiplatelet Using Cilostazol Versus Ticlopidine Undergoing Coronary Artery Stenting
- Analysis of Information Value Chains for Gout Self-Care Management" (2020)
- 2017 Preventive Generics Drug List
- Single and Multiple Dose Pharmacokinetics of Ticlopidine in Young and Elderly Subjects
- Successful Treatment of Severe Rheumatoid Vasculitis by Infliximab L Unger, M Kayser, H G Nüsslein
- Newer Anticoagulants • Describe Tests Which Detect Drug Presence • Describe the Wash-Out Periods • Outline Reversal in Urgent Situations
- Establishment of Framework for Classification/Categorisation and Labelling of Medicinal Drugs and Driving
- Platelet Inhibition with Cangrelor and Crushed Ticagrelor in STEMI Patients
- MODULATION of THROMBIN RECEPTOR SIGNALING By
- Ticlid Should Be Discontinued Temporarily Until the Danger of Abnormal Bleeding Is Eliminated